SURVEILLANCE (113): OMAN, ESCHERICHIA COLI, EXTENDED-SPECTRUM BETA-LACTAMASE, ANTIMICROBIAL RESI
Currently interpreted as supporting evidence for 1 tracked assessment.
Public note
For situational awareness and research transparency. Not medical advice.
System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.
Substantial confidence
Multiple lines of evidence are aligned, though the assessment remains provisional. Based on 4 linked evidence items and assessed against 365D.
02
The criteria the system uses to determine whether this assessment is borne out by the stated horizon.
Method
The condition the system checks for when evaluating this assessment.
Minimum source quality
Evidence must meet or exceed this credibility tier to count toward evaluation.
Required terms
beta-lactamasepmc12888852additional-lactamase03
Tracking since Apr 20, 2026.
06
The current analyst narrative for this scope.
AMR evidence pipeline severely constrained this cycle; two hypotheses resolve Apr 27 without confirmatory data; PubMed failure and stale secondary connectors limit incident coverage.
07
4 linked items.
Currently interpreted as supporting evidence for 1 tracked assessment.
Currently interpreted as supporting evidence for 1 tracked assessment.
Currently interpreted as supporting evidence for 1 tracked assessment.
Currently interpreted as supporting evidence for 1 tracked assessment.
Integrity anchor
Brier 0.202
19 resolved novel pathogen detection predictions.